By Fineline Cube 
Japan-based Shionogi Co., Ltd. has entered into an exclusive licensing agreement with Link Medical Products Pty Ltd, a subsidiary of the global specialty pharmaceutical services group Clinigen. The collaboration aims to advance the development and commercialization of cefiderocol in Australia and New Zealand.
Drug Profile
Cefiderocol is designed to treat infections caused by aerobic Gram-negative organisms in adults with limited treatment options. The drug is currently awaiting regulatory decisions in Australia, highlighting its potential to address unmet medical needs in the region.
Partnership Details
Under the terms of the agreement, Link Medical Products will hold exclusive development and commercialization rights for cefiderocol in Australia and New Zealand. Shionogi will receive an undisclosed upfront payment, along with milestone payments and royalties, reflecting the strategic value of this collaboration.-Fineline Info & Tech